{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:20:28Z","timestamp":1772767228133,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although genetic interventions are on the horizon for some polyglutamine expansion diseases, such as subtypes of spinocerebellar ataxia (SCA) and Huntington\u2019s disease (HD), the patients\u2019 preferences regarding these new therapies are unclear. This study aims to get insight into what extent different characteristics of genetic interventions affect the preferences of patients with SCA and HD with regard to these interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Manifest and premanifest patients with SCA or HD were recruited online by platforms of patient associations. The respondents conducted a questionnaire that included a discrete choice experiment (DCE). The experimental design included 24 choice sets, but these were divided into three blocks of eight to reduce the number of tasks per respondent. Each choice set included two alternative treatments and consisted of four attributes (mode and frequency of administration, chance of a beneficial effect, risks, and follow-up), each with three or four different levels. The forced choice-elicitation format was used. Data were analyzed by using a multinominal logistic regression model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Responses of 216 participants were collected. The mode and frequency of administration of a genetic intervention, as well as the chance of a beneficial effect both influence the choice for a genetic intervention. Respondents less prefer repeated lumbar punctures compared to a single operation. As expected, a higher beneficial effect of treatment was preferred. Risks and follow-up did not influence the choice for a genetic intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results can be used for the design and implementation of future genetic interventional trials as well as of patient-centered care pathways for rare movement disorders such as SCA and HD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-024-03408-2","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T05:17:06Z","timestamp":1730092626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preferences for genetic interventions for SCA and Huntington\u2019s disease: results of a discrete choice experiment among patients"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-7164","authenticated-orcid":false,"given":"Nienke J.H.","family":"van Os","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0732-4406","authenticated-orcid":false,"given":"Mayke","family":"Oosterloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7703-7114","authenticated-orcid":false,"given":"Janneke P.C.","family":"Grutters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2579-1561","authenticated-orcid":false,"given":"Brigitte A.B.","family":"Essers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4412-1616","authenticated-orcid":false,"given":"Bart P.C.","family":"van de Warrenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"issue":"6","key":"3408_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"A novel gene","year":"1993","unstructured":"A novel gene. Containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell. 1993;72(6):971\u201383.","journal-title":"Cell"},{"issue":"5","key":"3408_CR2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1055\/s-0031-1299785","volume":"31","author":"DS Verbeek","year":"2011","unstructured":"Verbeek DS, van de Warrenburg BP. Genetics of the dominant ataxias. Semin Neurol. 2011;31(5):461\u20139.","journal-title":"Semin Neurol"},{"issue":"2","key":"3408_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00415-018-9076-4","volume":"266","author":"R Sullivan","year":"2019","unstructured":"Sullivan R, Yau WY, O\u2019Connor E, Houlden H. Spinocerebellar ataxia: an update. J Neurol. 2019;266(2):533\u201344.","journal-title":"J Neurol"},{"issue":"1","key":"3408_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan P, Tabrizi SJ. Huntington\u2019s disease: a clinical review. Eur J Neurol. 2018;25(1):24\u201334.","journal-title":"Eur J Neurol"},{"issue":"7","key":"3408_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, Flower MD, Scahill RI, Wild EJ, et al. Potential disease-modifying therapies for Huntington\u2019s disease: lessons learned and future opportunities. Lancet Neurol. 2022;21(7):645\u201358.","journal-title":"Lancet Neurol"},{"issue":"12","key":"3408_CR6","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1002\/mds.28819","volume":"36","author":"Y V\u00e1zquez-Mojena","year":"2021","unstructured":"V\u00e1zquez-Mojena Y, Le\u00f3n-Arcia K, Gonz\u00e1lez-Zaldivar Y, Rodr\u00edguez-Labrada R, Vel\u00e1zquez-P\u00e9rez L. Gene Therapy for Polyglutamine Spinocerebellar ataxias: advances, challenges, and perspectives. Mov Disord. 2021;36(12):2731\u201344.","journal-title":"Mov Disord"},{"issue":"10","key":"3408_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","volume":"16","author":"SJ Tabrizi","year":"2020","unstructured":"Tabrizi SJ, Flower MD, Ross CA, Wild EJ. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol. 2020;16(10):529\u201346.","journal-title":"Nat Rev Neurol"},{"key":"3408_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/978-3-319-71779-1_20","volume":"1049","author":"CA Matos","year":"2018","unstructured":"Matos CA, Carmona V, Vijayakumar UG, Lopes S, Albuquerque P, Concei\u00e7\u00e3o M, et al. Gene therapies for Polyglutamine diseases. Adv Exp Med Biol. 2018;1049:395\u2013438.","journal-title":"Adv Exp Med Biol"},{"key":"3408_CR9","unstructured":"US FDA grants VICO Therapeutics Orphan-Drug Designation for VO. 659, an Investigational Therapy for Spinocerebellar Ataxia [updated 2021, June 29th. https:\/\/vicotx.com\/us-fda-grants-vico-therapeutics-orphan-drug-designation-for-vo659-an-investigational-therapy-for-spinocerebellar-ataxia\/"},{"key":"3408_CR10","unstructured":"Pharmacokinetics A. and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3 (clinicaltrials.gov) [updated May 2nd, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05160558"},{"issue":"1","key":"3408_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/ana.25264","volume":"84","author":"HS McLoughlin","year":"2018","unstructured":"McLoughlin HS, Moore LR, Chopra R, Komlo R, McKenzie M, Blumenstein KG, et al. Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice. Ann Neurol. 2018;84(1):64\u201377.","journal-title":"Ann Neurol"},{"issue":"24","key":"3408_CR12","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, et al. Targeting huntingtin expression in patients with Huntington\u2019s Disease. N Engl J Med. 2019;380(24):2307\u201316.","journal-title":"N Engl J Med"},{"issue":"6","key":"3408_CR13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamaneurol.2020.0299","volume":"77","author":"BR Leavitt","year":"2020","unstructured":"Leavitt BR, Kordasiewicz HB, Schobel SA. Huntingtin-lowering therapies for Huntington Disease: a review of the evidence of potential benefits and risks. JAMA Neurol. 2020;77(6):764\u201372.","journal-title":"JAMA Neurol"},{"issue":"4","key":"3408_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/JHD-160228","volume":"5","author":"JA Simpson","year":"2016","unstructured":"Simpson JA, Lovecky D, Kogan J, Vetter LA, Yohrling GJ. Survey of the Huntington\u2019s Disease patient and Caregiver Community reveals most impactful symptoms and treatment needs. J Huntingtons Dis. 2016;5(4):395\u2013403.","journal-title":"J Huntingtons Dis"},{"key":"3408_CR15","doi-asserted-by":"crossref","unstructured":"Gornick MC, Ryan KA, Dayalu P, Carlozzi NE, Albin RL, Zahuranec DB. Huntington\u2019s Disease Community Perspectives on Desired Characteristics of Disease Modifying Therapies. Tremor Other Hyperkinet Mov (N Y). 2021;11:3.","DOI":"10.5334\/tohm.584"},{"issue":"4","key":"3408_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/1077558712465774","volume":"70","author":"C Rathert","year":"2013","unstructured":"Rathert C, Wyrwich MD, Boren SA. Patient-centered care and outcomes: a systematic review of the literature. Med Care Res Rev. 2013;70(4):351\u201379.","journal-title":"Med Care Res Rev"},{"key":"3408_CR17","doi-asserted-by":"publisher","first-page":"237437352211254","DOI":"10.1177\/23743735221125439","volume":"9","author":"S Marzban","year":"2022","unstructured":"Marzban S, Najafi M, Agolli A, Ashrafi E. Impact of Patient Engagement on Healthcare Quality: a scoping review. J Patient Exp. 2022;9:23743735221125439.","journal-title":"J Patient Exp"},{"key":"3408_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4020-5753-3","volume-title":"Using Discrete Choice experiments to Value Health and Health Care","author":"M Ryan","year":"2008","unstructured":"Ryan M, Gerard K, Amaya-Amaya M. Using Discrete Choice experiments to Value Health and Health Care. Dordrecht: Springer; 2008."},{"issue":"2","key":"3408_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","volume":"37","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in Health Economics: past, Present and Future. PharmacoEconomics. 2019;37(2):201\u201326.","journal-title":"PharmacoEconomics"},{"issue":"4","key":"3408_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health\u2013a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403\u201313.","journal-title":"Value Health"},{"issue":"1","key":"3408_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3233\/JHD-180328","volume":"8","author":"TM Bardakjian","year":"2019","unstructured":"Bardakjian TM, Naczi KF, Gonzalez-Alegre P. Attitudes of potential participants towards molecular therapy trials in Huntington\u2019s Disease. J Huntingtons Dis. 2019;8(1):79\u201385.","journal-title":"J Huntingtons Dis"},{"issue":"1","key":"3408_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-021-02091-x","volume":"17","author":"G Thomas-Black","year":"2022","unstructured":"Thomas-Black G, Dumitrascu A, Garcia-Moreno H, Vallortigara J, Greenfield J, Hunt B, et al. The attitude of patients with progressive ataxias towards clinical trials. Orphanet J Rare Dis. 2022;17(1):1.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3408_CR23","doi-asserted-by":"publisher","first-page":"e0213649","DOI":"10.1371\/journal.pone.0213649","volume":"14","author":"H Landrum Peay","year":"2019","unstructured":"Landrum Peay H, Fischer R, Tzeng JP, Hesterlee SE, Morris C, Strong Martin A, et al. Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: a qualitative preference study of patients and parents. PLoS ONE. 2019;14(5):e0213649.","journal-title":"PLoS ONE"},{"issue":"1","key":"3408_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13023-019-1069-6","volume":"14","author":"RS Paquin","year":"2019","unstructured":"Paquin RS, Fischer R, Mansfield C, Mange B, Beaverson K, Ganot A, et al. Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best-worst scaling experiment in caregivers and adult patients. Orphanet J Rare Dis. 2019;14(1):102.","journal-title":"Orphanet J Rare Dis"},{"key":"3408_CR25","doi-asserted-by":"publisher","unstructured":"van Os NJH, Oosterloo M, Essers BAB, Grutters JPC, van de Warrenburg BPC. Genetic interventions for spinocerebellar ataxia and Huntington\u2019s disease: a qualitative study of the patient perspective. J Huntingtons Dis. 2024;13(3):321\u201328. https:\/\/doi.org\/10.3233\/JHD-240026.","DOI":"10.3233\/JHD-240026"},{"issue":"1","key":"3408_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0733-8619(05)70368-6","volume":"16","author":"RW Evans","year":"1998","unstructured":"Evans RW. Complications of lumbar puncture. Neurol Clin. 1998;16(1):83\u2013105.","journal-title":"Neurol Clin"},{"issue":"2","key":"3408_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jval.2018.07.876","volume":"22","author":"FR Johnson","year":"2019","unstructured":"Johnson FR, Yang JC, Reed SD. The Internal Validity of Discrete Choice Experiment Data: a Testing Tool for quantitative assessments. Value Health. 2019;22(2):157\u201360.","journal-title":"Value Health"},{"key":"3408_CR28","volume-title":"Getting started with Conjoint Analysis: strategies for product design and Pricing Research. Chapter 7: sample size issues for Conjoint Analysis","author":"B Orme","year":"2019","unstructured":"Orme B. Getting started with Conjoint Analysis: strategies for product design and Pricing Research. Chapter 7: sample size issues for Conjoint Analysis. Madison, Wisconsin: Research Publishers LCC; 2019."},{"issue":"5","key":"3408_CR29","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/hae.14383","volume":"27","author":"M Witkop","year":"2021","unstructured":"Witkop M, Morgan G, O\u2019Hara J, Recht M, Buckner TW, Nugent D, et al. Patient preferences and priorities for haemophilia gene therapy in the US: a discrete choice experiment. Haemophilia. 2021;27(5):769\u201382.","journal-title":"Haemophilia"},{"issue":"1","key":"3408_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-020-01667-3","volume":"16","author":"A Monnette","year":"2021","unstructured":"Monnette A, Chen E, Hong D, Bazzano A, Dixon S, Arnold WD, Shi L. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis. 2021;16(1):36.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3408_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1474-4422(10)70276-3","volume":"10","author":"SJ Tabrizi","year":"2011","unstructured":"Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, et al. Biological and clinical changes in premanifest and early stage Huntington\u2019s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011;10(1):31\u201342.","journal-title":"Lancet Neurol"},{"key":"3408_CR32","doi-asserted-by":"crossref","unstructured":"Byrne LM, Rodrigues FB, Johnson EB, Wijeratne PA, De Vita E, Alexander DC et al. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease. Sci Transl Med. 2018;10(458).","DOI":"10.1126\/scitranslmed.aat7108"},{"key":"3408_CR33","unstructured":"Statistics Netherlands: Highest achieved level of education by age and gender (Dutch only): Statistics Netherlands. 2022. https:\/\/www.cbs.nl\/nl-nl\/maatwerk\/2022\/47\/opleidingsniveau-16-naar-leeftijd-en-geslacht-2021"},{"issue":"6","key":"3408_CR34","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/hec.3354","volume":"26","author":"V Watson","year":"2017","unstructured":"Watson V, Becker F, de Bekker-Grob E. Discrete Choice Experiment Response Rates: a Meta-analysis. Health Econ. 2017;26(6):810\u20137.","journal-title":"Health Econ"},{"issue":"4","key":"3408_CR35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/hec.3626","volume":"27","author":"M Ryan","year":"2018","unstructured":"Ryan M, Krucien N, Hermens F. The eyes have it: using eye tracking to inform information processing strategies in multi-attributes choices. Health Econ. 2018;27(4):709\u201321.","journal-title":"Health Econ"},{"issue":"8","key":"3408_CR36","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/hec.1104","volume":"15","author":"E Lancsar","year":"2006","unstructured":"Lancsar E, Louviere J. Deleting \u2018irrational\u2019 responses from discrete choice experiments: a case of investigating or imposing preferences? Health Econ. 2006;15(8):797\u2013811.","journal-title":"Health Econ"},{"issue":"8","key":"3408_CR37","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user\u2019s guide. PharmacoEconomics. 2008;26(8):661\u201377.","journal-title":"PharmacoEconomics"},{"issue":"Pt 4","key":"3408_CR38","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/brain\/121.4.589","volume":"121","author":"T Klockgether","year":"1998","unstructured":"Klockgether T, L\u00fcdtke R, Kramer B, Abele M, B\u00fcrk K, Sch\u00f6ls L, et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain. 1998;121(Pt 4):589\u2013600.","journal-title":"Brain"},{"issue":"2","key":"3408_CR39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Unified Huntington\u2019s Disease Rating Scale","year":"1996","unstructured":"Unified Huntington\u2019s Disease Rating Scale. Reliability and consistency. Huntington Study Group. Mov Disord. 1996;11(2):136\u201342.","journal-title":"Mov Disord"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03408-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03408-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03408-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T09:19:40Z","timestamp":1730279980000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03408-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3408"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03408-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3576801\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"8 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Regional Committee on Research involving Human Subjects Arnhem-Nijmegen (file number: 2021\u20139700). Written informed consent was given by all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Bart van de Warrenburg receives research support from NOW, ZonMw, Hersenstichting, Radboud university medical center, the Brugling Fonds, and Gossweiler Foundation. The authors have stated explicitly that there are no conflicts of interest in connection with this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"398"}}